Ahf-Caltide, a Novel Polypeptide Derived from Calpastatin, Protects against Oxidative Stress Injury by Stabilizing...

Area of Science:

• Cardiovascular Biology
• Oxidative Stress Research
• Calcium Channel Modulation

Background:

• Reperfusion injury post-ischemia causes significant myocardial damage via oxidative stress (OS).
• Imbalances in calcium homeostasis are critical contributors to OS-induced myocardial injury.
• The Ca_V1.2 calcium channel regulates calcium entry into cardiomyocytes and is modulated by calpastatin (CAST) domain L, specifically CS_L54-64.

Purpose of the Study:

• To investigate the cardioprotective effects of Ahf-caltide, a derivative of CS_L54-64, against myocardial OS injury.
• To elucidate the mechanism by which Ahf-caltide impacts calcium homeostasis and cellular survival under OS conditions.

Main Methods:

• Administration of Ahf-caltide to models of myocardial OS injury.
• Assessment of biochemical markers (LDH, MDA, ROS, SOD) and physiological parameters (heart rate, coronary flow).
• Analysis of protein expression levels (Ca_V1.2, Ca_Vβ2, CAST) and cellular uptake of Ahf-caltide.
• Investigation of CS_L binding to the Ca_V1.2 channel under varying calcium and H₂O₂ concentrations.

Main Results:

• Ahf-caltide significantly reduced markers of cell damage (LDH, MDA, ROS) and improved cell survival.
• Treatment with Ahf-caltide increased heart rate, coronary flow, and SOD activity.
• Ahf-caltide enhanced the expression of Ca_V1.2, Ca_Vβ2, and CAST by inhibiting protein degradation.
• CS_L54-64 was identified as the key region responsible for binding to the Ca_V1.2 channel, with binding increasing in an H₂O₂-dependent manner.

Conclusions:

• Ahf-caltide demonstrates significant cardioprotective effects against myocardial OS injury by stabilizing Ca_V1.2 protein expression.
• Restoring calcium homeostasis via targeting the Ca_V1.2 channel and CAST presents a novel therapeutic strategy for myocardial OS injury.